

CARDIAC TISSUE DOPPLER ECHOCARDIOGRAPHIC EVALUATION OF PATIENTS WITH PROLACTINOMA TREATED WITH CABERGOLINE

Dr.Mustafa Tasdelen², Dr.Senay Arikan Durmaz¹, Dr.Nesligul Yildirim³, Dr.Aydin Cifci², Dr.Askin Gungunes¹

- ¹ Kirikkale University Faculty of Medicine, Department of Endocrinology, Kirikkale, Turkey
- ²Kirikkale University Faculty of Medicine, Department of Internal Medicine, Kirikkale, Turkey.
- ³ Kirikkale University Faculty of Medicine, Department of Cardiology, Kirikkale, Turkey

Introduction

There are few side effects of cabergoline which is used for medical treatment of prolactinoma. For this reason, cabergoline is considered as first-line therapy of prolactinoma. However, chronic administration of high dose cabergoline in patients with prolactinoma may be associated with valvular heart disease. The aim of this study is to evaluate left ventricular systolic and diastolic functions by conventional and tissue doppler echocardiography in patients with prolactinoma who have been chronically treated with cabergoline.

Methods

A total of 30 patients with prolactinoma who have been treated with cabergoline [mean age 33.4±8.5 years and body mass index (BMI): 28.1±7.8 kg/m²] were included in this study. Thirty (mean age 30.0±9.8 BMI-matched and ageyears; BMI: 26.8±6.4 kg/m²) hyperprolactinemia patients without cabergoline treatment were also included, and 30 age- and BMI-matched healthy subjects (mean age 31.0±7.0 years; BMI: 25.2±2.9 kg/m²) were assigned to control group. Cumulative cabergoline dose in patients with prolactinoma was calculated as 218 mg. Mean duration of cabergoline therapy was 121.9±98.5 weeks (range 52-468 weeks). All patients transthoracic tissue evaluated by and doppler were echocardiography. Left ventricle systolic and diastolic functions and left ventricle, left atrium diameters were measured.

All biochemical and hormonal analysis were performed by automatic analyzer.

Results

According to our data, serum prolactin levels were 35.5±39.5 ng/ml in prolactinoma group during cabergoline treatment, 58.3±40.5 ng/ml in hyperprolactinemia group without cabergoline treatment and 16.2±8.3 ng/ml in control group. Left ventricle systolic and diastolic functions parameters were normal among all of the study groups.

Prolactinoma group (A)	Hyperprolactinemia group (B)	Control (C)	P A-B	P A-C	P B-C
8,09±0,97	8,46±1,22	8,29±0,97	NS	NS	NS
31,75±6,61	30,19±8,12	30,92±7	NS	NS	NS
44,9±3,73	43,56±3,46	44,24±3,85	NS	NS	NS
27,99±3,04	27,47±2,63	27,77±2,86	NS	NS	NS
67,94±5,39	66,93±4,1	67,94± 3,1	NS	NS	NS
21,38±3,83	21,15±3,93	21,88± 4,36	NS	NS	NS
76,1±14,1	80,36±14,04	77,1±17,35	NS	NS	NS
63,73±9,82	66,66±9,34	62,2±10,48	NS	NS	NS
1,21±0,3	1,23±0,26	1,3±0,21	NS	NS	NS
185,78±53,51	191,48±35,14	177,36±44,54	NS	NS	NS
11,56±2,178	13,4±3,65	13,23±3,51	NS	NS	NS
8,37±1,83	8,93±2,05	8,6±2	NS	NS	NS
8,61±1,85	8,95±1,88	8,60±1,34	NS	NS	NS
6,73±1,79	6,08±1,3	6,48±2,05	NS	NS	NS
	group (A) n:30 8,09±0,97 31,75±6,61 44,9±3,73 27,99±3,04 67,94±5,39 21,38±3,83 76,1±14,1 63,73±9,82 1,21±0,3 185,78±53,51 11,56±2,178 8,37±1,83 8,61±1,85	group (A) group (B) n:30 n:30 8,09±0,97 8,46±1,22 31,75±6,61 30,19±8,12 44,9±3,73 43,56±3,46 27,99±3,04 27,47±2,63 67,94±5,39 66,93±4,1 21,38±3,83 21,15±3,93 76,1±14,1 80,36±14,04 63,73±9,82 66,66±9,34 1,21±0,3 1,23±0,26 185,78±53,51 191,48±35,14 11,56±2,178 13,4±3,65 8,37±1,83 8,93±2,05 8,61±1,85 8,95±1,88	group (A) group (B) (C) n:30 n:30 n:30 8,09±0,97 8,46±1,22 8,29±0,97 31,75±6,61 30,19±8,12 30,92±7 44,9±3,73 43,56±3,46 44,24±3,85 27,99±3,04 27,47±2,63 27,77±2,86 67,94±5,39 66,93±4,1 67,94±3,1 21,38±3,83 21,15±3,93 21,88±4,36 76,1±14,1 80,36±14,04 77,1±17,35 63,73±9,82 66,66±9,34 62,2±10,48 1,21±0,3 1,23±0,26 1,3±0,21 185,78±53,51 191,48±35,14 177,36±44,54 11,56±2,178 13,4±3,65 13,23±3,51 8,37±1,83 8,93±2,05 8,6±2 8,61±1,85 8,95±1,88 8,60±1,34	group (A) group (B) (C) A-B 8,09±0,97 8,46±1,22 8,29±0,97 NS 31,75±6,61 30,19±8,12 30,92±7 NS 44,9±3,73 43,56±3,46 44,24±3,85 NS 27,99±3,04 27,47±2,63 27,77±2,86 NS 67,94±5,39 66,93±4,1 67,94±3,1 NS 21,38±3,83 21,15±3,93 21,88±4,36 NS 76,1±14,1 80,36±14,04 77,1±17,35 NS 63,73±9,82 66,66±9,34 62,2±10,48 NS 1,21±0,3 1,23±0,26 1,3±0,21 NS 185,78±53,51 191,48±35,14 177,36±44,54 NS 11,56±2,178 13,4±3,65 13,23±3,51 NS 8,37±1,83 8,93±2,05 8,6±2 NS 8,61±1,85 8,95±1,88 8,60±1,34 NS	group (A) group (B) (C) A-B A-C 8,09±0,97 8,46±1,22 8,29±0,97 NS NS 31,75±6,61 30,19±8,12 30,92±7 NS NS 44,9±3,73 43,56±3,46 44,24±3,85 NS NS 27,99±3,04 27,47±2,63 27,77±2,86 NS NS 67,94±5,39 66,93±4,1 67,94±3,1 NS NS 21,38±3,83 21,15±3,93 21,88±4,36 NS NS 76,1±14,1 80,36±14,04 77,1±17,35 NS NS 63,73±9,82 66,66±9,34 62,2±10,48 NS NS 1,21±0,3 1,23±0,26 1,3±0,21 NS NS 185,78±53,51 191,48±35,14 177,36±44,54 NS NS 11,56±2,178 13,4±3,65 13,23±3,51 NS NS 8,37±1,83 8,93±2,05 8,6±2 NS NS 8,61±1,85 8,95±1,88 8,60±1,34 NS NS




FIGURE 1: Positive correlation between cumulative cabergoline dose and deceleration time (DT) (r=0.369, p=<0.001)

Conclusions

Low-dose cabergoline in patients with prolactinoma is not associated with cardiac valvular dysfunction and also left ventricular systolic and diastolic dysfunction by conventional and tissue doppler echocardiography. However, high cumulative cabergoline dose may relate to increase in DT and Am parameters that may be related to diastolic dysfunction in the future.

ECE2016



Pituitary - Clinical

Mustafa Rasid





